Cachexia, a systemic wasting condition, is considered a late consequence of diseases,
including cancer, organ failure, or infections, and contributes to significant morbidity and …

Introduction Hepatocellular carcinoma (HCC) is the most common primary liver cancer and
fourth-leading cause of cancer death. While drug discovery to improve disease survival was …

Simple Summary Immunotherapy is now the standard front-line therapy for patients with
advanced hepatocellular carcinoma. However, there remains a substantial proportion of …

Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …

Abstract Background & Aims Immune checkpoint inhibitors (ICIs) alone or in combination
with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic …

Background A growing body of evidence suggests that non-viral hepatocellular carcinoma
(HCC) might benefit less from immunotherapy. Materials and methods We carried out a …

Objective Our study represents the first meta-analysis conducted to evaluate the prognostic
utility of the baseline prognostic nutritional index (PNI) in patients with gastrointestinal …

The treatment landscape of advanced hepatocellular carcinoma (HCC) has broadened with
immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths
worldwide. To date, systemic treatment for patients with unresectable or advanced disease …

Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with
advanced-stage hepatocellular carcinoma (HCC). Two different ICI-containing regimens …